Pharmaceutical - AstraZeneca, Pharmaceutical

Filter

Current filters:

AstraZenecaPharmaceutical

Popular Filters

1 to 25 of 319 results

AstraZeneca study of Brilinta meets primary endpoint

AstraZeneca study of Brilinta meets primary endpoint

14-01-2015

Anglo-Swedish drug major AstraZeneca has announced its PEGASUS-TIMI 54 study of Brilinta (ticagrelor)…

AstraZenecaBrilintaCardio-vascularPharmaceuticalResearch

In 2014, FDA approved highest number of new drugs in 18 years

In 2014, FDA approved highest number of new drugs in 18 years

04-01-2015

The US Food and Drug Administration's Center for Drug Evaluation and Research approved 41 novel medicines…

AstraZenecaGilead SciencesPharmaceuticalRegulationUSA

AstraZeneca’s Lynparza gains FDA approval

AstraZeneca’s Lynparza gains FDA approval

20-12-2014

The US Food and Drug Administration has granted accelerated approved for Anglo-Swedish drug major AstraZeneca’s…

AstraZenecaLynparzaOncologyPharmaceuticalRegulationUSA

European Commission grants marketing authorization to AstraZeneca's Lynparza

European Commission grants marketing authorization to AstraZeneca's Lynparza

18-12-2014

Anglo-Swedish drug major AstraZeneca has received marketing authorization from the European Commission…

AstraZenecaLynparzaOncologyPharmaceuticalRegulation

Patent cliff means pharma will lose $65 billion by 2019, says report

Patent cliff means pharma will lose $65 billion by 2019, says report

11-12-2014

Pharmaceutical companies will suffer an estimated $65 billion drop in sales by 2019 due to the patent…

AbilifyAstraZenecaEli LillyGlobalMarkets & MarketingNeurologicalOtsukaPatentsPharmaceuticalSeroquelZyprexa

AstraZeneca’s Moventig gains EU approval for OIC

09-12-2014

The European Commission has granted marketing authorization for Anglo-Swedish pharma major AstraZeneca’s…

AstraZenecaEuropeGastro-intestinalsMoventigNektar TherapeuticsPharmaceuticalRegulation

World’s largest collection of deprioritized pharma compounds opens to researchers

World’s largest collection of deprioritized pharma compounds opens to researchers

09-12-2014

A collection of 68 deprioritized pharmaceutical compounds is being made available to academic researchers…

AstraZenecaEli LillyGlaxoSmithKlineJanssen Research & DevelopmentPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

FDA advisory panel backs Actavis’ ceftazidime-avibactam

06-12-2014

Ireland-headquartered generic drugs major Actavis says that the Anti-Infective Drugs Advisory Committee…

ActavisAntibiotics and Infectious diseasesAstraZenecaceftazidime-avibactamPharmaceuticalRegulationUSA

Patient access to novel non-insulin treatments is sub-optimal in China

05-12-2014

With respect to the treatment of type 2 diabetes in China, patient access to premium-priced agents is…

AstraZenecaByettaChinaDiabetesHealthcareJanuviaMarkets & MarketingMerck & CoPharmaceutical

Eli Lilly and AstraZeneca enrol first patient in Phase II/III Alzheimer's therapy trial

Eli Lilly and AstraZeneca enrol first patient in Phase II/III Alzheimer's therapy trial

02-12-2014

US drug major Eli Lilly and AstraZeneca have enrolled the first patient into AMARANTH, a Phase II/III…

AstraZenecaAZD3293Eli LillyNeurologicalPharmaceuticalResearch

FDA accepts NDA filing from AstraZeneca for Iressa

FDA accepts NDA filing from AstraZeneca for Iressa

02-12-2014

The US Food and Drug Administration has accepted for filing the New Drug Application from Iressa (gefitinib)…

AstraZenecaIressaOncologyPharmaceuticalRegulationUK

AstraZeneca signs drug discovery collaboration with Cancer Research UK

AstraZeneca signs drug discovery collaboration with Cancer Research UK

28-11-2014

UK pharma major AstraZeneca and charity Cancer Research UK have signed a memorandum of understanding…

AstraZenecaOncologyPharmaceuticalResearchUK

Asthma drug market set to grow $23 billion by 2023

28-11-2014

The asthma treatment market value will grow across eight major countries (the USA, UK, France, Germany,…

AdvairAstraZenecaAustraliaEuropeGlaxoSmithKlineJapanMarkets & MarketingMerck & CoPharmaceuticalRespiratory and PulmonarySingulairSymbicortUSA

MHRA showcases benefit of its industry collaboration with AstraZeneca's Macclesfield plant

MHRA showcases benefit of its industry collaboration with AstraZeneca's Macclesfield plant

27-11-2014

The UK's Medicines and Healthcare products Regulatory Agency has published a case study outlining the…

AstraZenecaOncologyPharmaceuticalProductionUK

Amgen/AstraZeneca's brodalumab trial meets primary endpoints for moderate-to-severe plaque psoriasis

Amgen/AstraZeneca's brodalumab trial meets primary endpoints for moderate-to-severe plaque psoriasis

26-11-2014

USA-based Amgen, the world’s leading independent biotech firm, and Anglo-Swedish drug major AstraZeneca…

AmgenAstraZenecabrodalumabDermatologicalsPharmaceuticalResearch

AstraZeneca plans further Russian expansion

25-11-2014

Anglo-Swedish pharma major AstraZeneca plans to continue active development on the Russian pharmaceutical…

AstraZenecaFinancialPharmaceuticalProductionRussia

AstraZeneca’s Duaklir Genuair approved in the EU for COPD

AstraZeneca’s Duaklir Genuair approved in the EU for COPD

25-11-2014

The European Commission has granted marketing authorization for Anglo-Swedish pharma major AstraZeneca’s…

AstraZenecaDuaklir GenuairPharmaceuticalRegulationRespiratory and PulmonaryUK

European prescribing trends for mCR prostate cancer

20-11-2014

Johnson & Johnson/AstraZeneca’s Zytiga (abiraterone acetate) is the clear agent of choice for second-line…

Astellas PharmaAstraZenecaBayerDendreonFranceGermanyItalyJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalProvengeSpainUKXofigoXtandiZytiga

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

Positive Ph III data for AstraZeneca’s lesinurad in gout patients

17-11-2014

Anglo-Swedish pharma major AstraZeneca has presented positive top-line results of two pivotal Phase III…

allopurinolAnti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

SMC accepts Eylea and Onglyza for use in NHS Scotland

SMC accepts Eylea and Onglyza for use in NHS Scotland

13-11-2014

The Scottish Medicines Consortium (SMC) has accepted German drugmaker Bayer’s Eylea (aflibercept solution…

AstraZenecaBayerDiabetesEyleaOnglyzaPharmaceuticalRegulationUK

Almirall profits leap in first nine months of 2014

Almirall profits leap in first nine months of 2014

10-11-2014

Almirall, Spain’s largest drugmaker, has reported strong financial results for the first-three quarters…

AlmirallAstraZenecaEkliraFinancialPharmaceuticalSpain

AstraZeneca’s olaparib shows success in tumor response rate for patients with BRCA-related cancers

07-11-2014

Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26%…

AstraZenecaLynparzaolaparibOncologyPharmaceuticalResearch

AstraZeneca raises forecast on strong third quarter

AstraZeneca raises forecast on strong third quarter

06-11-2014

AstraZeneca, the Anglo-Swedish pharma major which defended itself against a £73.82 billion ($118 billion)…

AstraZenecaFinancialPharmaceutical

1 to 25 of 319 results

Back to top